Ranked No. 1 in Manufacturing of PCB Handling Equipment in Korea 31/05/2018 — SEOUL, South Korea — (BUSINESS WIRE) YJ Link Co., Ltd., a company specializing in the manufacturing of […]
26/04/2018 — HAMILTON, Bermuda — (BUSINESS WIRE) Jeffrey Gannon and Adrian Dunner, in partnership with investment vehicles managed by Wafra Inc., today announced the formation of Global Container International LLC […]
Announces significant stake in Hyundai Mobis, Hyundai Motor, and Kia Motors Seeks stronger commitment to governance improvements and enhanced capital returns 03/04/2018 — HONG KONG — (BUSINESS WIRE) Elliott Advisors […]
New Gameplay Preview Video Footage Shows Google Maps API in Action 19/03/2018 — SEOUL, South Korea — (BUSINESS WIRE) The recently announced Ghostbusters World, developed in collaboration between Sony Pictures […]
10/02/2018 — PYEONGCHANG, Korea & HANGZHOU, China — (BUSINESS WIRE) Alibaba Group (NYSE:BABA), the world’s largest retail commerce company, kicked off its first Olympic Games as a TOP partner today […]
22/09/2017 — SEOUL, South Korea — (BUSINESS WIRE) Mobile RPG “King’s Raid” which was launched in February in Korea, North America and SEA, is officially launching in European Markets (Google […]
Samsung Bioepis’ Flixabi® receives positive opinion from the Committee for Medicinal Products for Human Use, meets the European Medicines Agency’s requirements on the quality, efficacy and safety of biosimilars Flixabi® […]
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Benepali® – a biosimilar referencing Enbrel® (etanercept), also known as SB4 – for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and plaque psoriasis. The EC approval follows a positive opinion on Benepali® by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which was announced on November 20, 2015.
The Estée Lauder Companies Inc. (NYSE:EL) announced today that it has completed its investment in Have & Be Co. Ltd., the South Korean company behind skin care brands Dr. Jart+ and Do The Right Thing. Terms of the investment were not disclosed. Launched online in 2005 by ChinWook Lee, Dr. Jart+ is a Seoul-based, global high-growth skin care brand featuring quality and innovative products designed to address specific skin care needs. The brand’s unique fusion of dermatological science and art – as reflected in the brand name, which is inspired by the phrase “Doctor Joins Art” – appeals to a broad range of consumers, especially millennials. Dr. Jart+ is sold in many countries around the world, primarily in Asia and the United States, through various department stores, specialty-multi and e-commerce channels including Sephora.
Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® (infliximab), also known as SB2 – for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis and plaque psoriasis. This marks the second regulatory approval for Samsung Bioepis in Korea. The MFDS approved in September 2015 Samsung Bioepis’ BRENZYS®, a biosimilar version of Enbrel® (etanercept), also known as SB4.